Report cover image

Global Irbesartan Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 216 Pages
SKU # APRC20359934

Description

Summary

According to APO Research, the global Irbesartan market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Irbesartan is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Irbesartan is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Irbesartan market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Irbesartan is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Irbesartan market include Angita Pharma, Apotex, Auro Pharma, Avanstra, BMS, Hanall, Shionogi, Sumitomo Dainippon Pharma and Taj Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Irbesartan, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Irbesartan, also provides the sales of main regions and countries. Of the upcoming market potential for Irbesartan, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Irbesartan sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Irbesartan market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Irbesartan sales, projected growth trends, production technology, application and end-user industry.

Irbesartan Segment by Company

Angita Pharma
Apotex
Auro Pharma
Avanstra
BMS
Hanall
Shionogi
Sumitomo Dainippon Pharma
Taj Pharmaceuticals
Verdant Life Sciences
Jiangsu Hengrui Medicine
Jiangsu Wangao Pharmaceutical
CTTQ
Novartis
Sanofi
Teva
Tianjin Huairen Pharmaceutical
Xiansheng Pharmaceutical
Yuanhe Pharmaceutical
Zhejiang Ainuo Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhuhai Rundu Pharma
Irbesartan Segment by Type

Combination Drugs
Prescribed Drugs
Irbesartan Segment by Application

Heart Failure
Fibrous Fibrillation
Kidney Disease
Hyperlipidemia
High Blood Pressure
Other
Irbesartan Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Irbesartan status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Irbesartan market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Irbesartan significant trends, drivers, influence factors in global and regions.
6. To analyze Irbesartan competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irbesartan market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irbesartan and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irbesartan.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Irbesartan market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Irbesartan industry.
Chapter 3: Detailed analysis of Irbesartan manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Irbesartan in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Irbesartan in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

216 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Irbesartan Sales Value (2020-2031)
1.2.2 Global Irbesartan Sales Volume (2020-2031)
1.2.3 Global Irbesartan Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Irbesartan Market Dynamics
2.1 Irbesartan Industry Trends
2.2 Irbesartan Industry Drivers
2.3 Irbesartan Industry Opportunities and Challenges
2.4 Irbesartan Industry Restraints
3 Irbesartan Market by Company
3.1 Global Irbesartan Company Revenue Ranking in 2024
3.2 Global Irbesartan Revenue by Company (2020-2025)
3.3 Global Irbesartan Sales Volume by Company (2020-2025)
3.4 Global Irbesartan Average Price by Company (2020-2025)
3.5 Global Irbesartan Company Ranking (2023-2025)
3.6 Global Irbesartan Company Manufacturing Base and Headquarters
3.7 Global Irbesartan Company Product Type and Application
3.8 Global Irbesartan Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Irbesartan Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Irbesartan Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Irbesartan Market by Type
4.1 Irbesartan Type Introduction
4.1.1 Combination Drugs
4.1.2 Prescribed Drugs
4.2 Global Irbesartan Sales Volume by Type
4.2.1 Global Irbesartan Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Irbesartan Sales Volume by Type (2020-2031)
4.2.3 Global Irbesartan Sales Volume Share by Type (2020-2031)
4.3 Global Irbesartan Sales Value by Type
4.3.1 Global Irbesartan Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Irbesartan Sales Value by Type (2020-2031)
4.3.3 Global Irbesartan Sales Value Share by Type (2020-2031)
5 Irbesartan Market by Application
5.1 Irbesartan Application Introduction
5.1.1 Heart Failure
5.1.2 Fibrous Fibrillation
5.1.3 Kidney Disease
5.1.4 Hyperlipidemia
5.1.5 High Blood Pressure
5.1.6 Other
5.2 Global Irbesartan Sales Volume by Application
5.2.1 Global Irbesartan Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Irbesartan Sales Volume by Application (2020-2031)
5.2.3 Global Irbesartan Sales Volume Share by Application (2020-2031)
5.3 Global Irbesartan Sales Value by Application
5.3.1 Global Irbesartan Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Irbesartan Sales Value by Application (2020-2031)
5.3.3 Global Irbesartan Sales Value Share by Application (2020-2031)
6 Irbesartan Regional Sales and Value Analysis
6.1 Global Irbesartan Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Irbesartan Sales by Region (2020-2031)
6.2.1 Global Irbesartan Sales by Region: 2020-2025
6.2.2 Global Irbesartan Sales by Region (2026-2031)
6.3 Global Irbesartan Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Irbesartan Sales Value by Region (2020-2031)
6.4.1 Global Irbesartan Sales Value by Region: 2020-2025
6.4.2 Global Irbesartan Sales Value by Region (2026-2031)
6.5 Global Irbesartan Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Irbesartan Sales Value (2020-2031)
6.6.2 North America Irbesartan Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Irbesartan Sales Value (2020-2031)
6.7.2 Europe Irbesartan Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Irbesartan Sales Value (2020-2031)
6.8.2 Asia-Pacific Irbesartan Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Irbesartan Sales Value (2020-2031)
6.9.2 South America Irbesartan Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Irbesartan Sales Value (2020-2031)
6.10.2 Middle East & Africa Irbesartan Sales Value Share by Country, 2024 VS 2031
7 Irbesartan Country-level Sales and Value Analysis
7.1 Global Irbesartan Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Irbesartan Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Irbesartan Sales by Country (2020-2031)
7.3.1 Global Irbesartan Sales by Country (2020-2025)
7.3.2 Global Irbesartan Sales by Country (2026-2031)
7.4 Global Irbesartan Sales Value by Country (2020-2031)
7.4.1 Global Irbesartan Sales Value by Country (2020-2025)
7.4.2 Global Irbesartan Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Irbesartan Sales Value Growth Rate (2020-2031)
7.5.2 USA Irbesartan Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Irbesartan Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Irbesartan Sales Value Growth Rate (2020-2031)
7.6.2 Canada Irbesartan Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Irbesartan Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Irbesartan Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Irbesartan Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Irbesartan Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Irbesartan Sales Value Growth Rate (2020-2031)
7.8.2 Germany Irbesartan Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Irbesartan Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Irbesartan Sales Value Growth Rate (2020-2031)
7.9.2 France Irbesartan Sales Value Share by Type, 2024 VS 2031
7.9.3 France Irbesartan Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Irbesartan Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Irbesartan Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Irbesartan Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Irbesartan Sales Value Growth Rate (2020-2031)
7.11.2 Italy Irbesartan Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Irbesartan Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Irbesartan Sales Value Growth Rate (2020-2031)
7.12.2 Spain Irbesartan Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Irbesartan Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Irbesartan Sales Value Growth Rate (2020-2031)
7.13.2 Russia Irbesartan Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Irbesartan Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Irbesartan Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Irbesartan Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Irbesartan Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Irbesartan Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Irbesartan Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Irbesartan Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Irbesartan Sales Value Growth Rate (2020-2031)
7.16.2 China Irbesartan Sales Value Share by Type, 2024 VS 2031
7.16.3 China Irbesartan Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Irbesartan Sales Value Growth Rate (2020-2031)
7.17.2 Japan Irbesartan Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Irbesartan Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Irbesartan Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Irbesartan Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Irbesartan Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Irbesartan Sales Value Growth Rate (2020-2031)
7.19.2 India Irbesartan Sales Value Share by Type, 2024 VS 2031
7.19.3 India Irbesartan Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Irbesartan Sales Value Growth Rate (2020-2031)
7.20.2 Australia Irbesartan Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Irbesartan Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Irbesartan Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Irbesartan Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Irbesartan Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Irbesartan Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Irbesartan Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Irbesartan Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Irbesartan Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Irbesartan Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Irbesartan Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Irbesartan Sales Value Growth Rate (2020-2031)
7.24.2 Chile Irbesartan Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Irbesartan Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Irbesartan Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Irbesartan Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Irbesartan Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Irbesartan Sales Value Growth Rate (2020-2031)
7.26.2 Peru Irbesartan Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Irbesartan Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Irbesartan Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Irbesartan Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Irbesartan Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Irbesartan Sales Value Growth Rate (2020-2031)
7.28.2 Israel Irbesartan Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Irbesartan Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Irbesartan Sales Value Growth Rate (2020-2031)
7.29.2 UAE Irbesartan Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Irbesartan Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Irbesartan Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Irbesartan Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Irbesartan Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Irbesartan Sales Value Growth Rate (2020-2031)
7.31.2 Iran Irbesartan Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Irbesartan Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Irbesartan Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Irbesartan Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Irbesartan Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Angita Pharma
8.1.1 Angita Pharma Comapny Information
8.1.2 Angita Pharma Business Overview
8.1.3 Angita Pharma Irbesartan Sales, Value and Gross Margin (2020-2025)
8.1.4 Angita Pharma Irbesartan Product Portfolio
8.1.5 Angita Pharma Recent Developments
8.2 Apotex
8.2.1 Apotex Comapny Information
8.2.2 Apotex Business Overview
8.2.3 Apotex Irbesartan Sales, Value and Gross Margin (2020-2025)
8.2.4 Apotex Irbesartan Product Portfolio
8.2.5 Apotex Recent Developments
8.3 Auro Pharma
8.3.1 Auro Pharma Comapny Information
8.3.2 Auro Pharma Business Overview
8.3.3 Auro Pharma Irbesartan Sales, Value and Gross Margin (2020-2025)
8.3.4 Auro Pharma Irbesartan Product Portfolio
8.3.5 Auro Pharma Recent Developments
8.4 Avanstra
8.4.1 Avanstra Comapny Information
8.4.2 Avanstra Business Overview
8.4.3 Avanstra Irbesartan Sales, Value and Gross Margin (2020-2025)
8.4.4 Avanstra Irbesartan Product Portfolio
8.4.5 Avanstra Recent Developments
8.5 BMS
8.5.1 BMS Comapny Information
8.5.2 BMS Business Overview
8.5.3 BMS Irbesartan Sales, Value and Gross Margin (2020-2025)
8.5.4 BMS Irbesartan Product Portfolio
8.5.5 BMS Recent Developments
8.6 Hanall
8.6.1 Hanall Comapny Information
8.6.2 Hanall Business Overview
8.6.3 Hanall Irbesartan Sales, Value and Gross Margin (2020-2025)
8.6.4 Hanall Irbesartan Product Portfolio
8.6.5 Hanall Recent Developments
8.7 Shionogi
8.7.1 Shionogi Comapny Information
8.7.2 Shionogi Business Overview
8.7.3 Shionogi Irbesartan Sales, Value and Gross Margin (2020-2025)
8.7.4 Shionogi Irbesartan Product Portfolio
8.7.5 Shionogi Recent Developments
8.8 Sumitomo Dainippon Pharma
8.8.1 Sumitomo Dainippon Pharma Comapny Information
8.8.2 Sumitomo Dainippon Pharma Business Overview
8.8.3 Sumitomo Dainippon Pharma Irbesartan Sales, Value and Gross Margin (2020-2025)
8.8.4 Sumitomo Dainippon Pharma Irbesartan Product Portfolio
8.8.5 Sumitomo Dainippon Pharma Recent Developments
8.9 Taj Pharmaceuticals
8.9.1 Taj Pharmaceuticals Comapny Information
8.9.2 Taj Pharmaceuticals Business Overview
8.9.3 Taj Pharmaceuticals Irbesartan Sales, Value and Gross Margin (2020-2025)
8.9.4 Taj Pharmaceuticals Irbesartan Product Portfolio
8.9.5 Taj Pharmaceuticals Recent Developments
8.10 Verdant Life Sciences
8.10.1 Verdant Life Sciences Comapny Information
8.10.2 Verdant Life Sciences Business Overview
8.10.3 Verdant Life Sciences Irbesartan Sales, Value and Gross Margin (2020-2025)
8.10.4 Verdant Life Sciences Irbesartan Product Portfolio
8.10.5 Verdant Life Sciences Recent Developments
8.11 Jiangsu Hengrui Medicine
8.11.1 Jiangsu Hengrui Medicine Comapny Information
8.11.2 Jiangsu Hengrui Medicine Business Overview
8.11.3 Jiangsu Hengrui Medicine Irbesartan Sales, Value and Gross Margin (2020-2025)
8.11.4 Jiangsu Hengrui Medicine Irbesartan Product Portfolio
8.11.5 Jiangsu Hengrui Medicine Recent Developments
8.12 Jiangsu Wangao Pharmaceutical
8.12.1 Jiangsu Wangao Pharmaceutical Comapny Information
8.12.2 Jiangsu Wangao Pharmaceutical Business Overview
8.12.3 Jiangsu Wangao Pharmaceutical Irbesartan Sales, Value and Gross Margin (2020-2025)
8.12.4 Jiangsu Wangao Pharmaceutical Irbesartan Product Portfolio
8.12.5 Jiangsu Wangao Pharmaceutical Recent Developments
8.13 CTTQ
8.13.1 CTTQ Comapny Information
8.13.2 CTTQ Business Overview
8.13.3 CTTQ Irbesartan Sales, Value and Gross Margin (2020-2025)
8.13.4 CTTQ Irbesartan Product Portfolio
8.13.5 CTTQ Recent Developments
8.14 Novartis
8.14.1 Novartis Comapny Information
8.14.2 Novartis Business Overview
8.14.3 Novartis Irbesartan Sales, Value and Gross Margin (2020-2025)
8.14.4 Novartis Irbesartan Product Portfolio
8.14.5 Novartis Recent Developments
8.15 Sanofi
8.15.1 Sanofi Comapny Information
8.15.2 Sanofi Business Overview
8.15.3 Sanofi Irbesartan Sales, Value and Gross Margin (2020-2025)
8.15.4 Sanofi Irbesartan Product Portfolio
8.15.5 Sanofi Recent Developments
8.16 Teva
8.16.1 Teva Comapny Information
8.16.2 Teva Business Overview
8.16.3 Teva Irbesartan Sales, Value and Gross Margin (2020-2025)
8.16.4 Teva Irbesartan Product Portfolio
8.16.5 Teva Recent Developments
8.17 Tianjin Huairen Pharmaceutical
8.17.1 Tianjin Huairen Pharmaceutical Comapny Information
8.17.2 Tianjin Huairen Pharmaceutical Business Overview
8.17.3 Tianjin Huairen Pharmaceutical Irbesartan Sales, Value and Gross Margin (2020-2025)
8.17.4 Tianjin Huairen Pharmaceutical Irbesartan Product Portfolio
8.17.5 Tianjin Huairen Pharmaceutical Recent Developments
8.18 Xiansheng Pharmaceutical
8.18.1 Xiansheng Pharmaceutical Comapny Information
8.18.2 Xiansheng Pharmaceutical Business Overview
8.18.3 Xiansheng Pharmaceutical Irbesartan Sales, Value and Gross Margin (2020-2025)
8.18.4 Xiansheng Pharmaceutical Irbesartan Product Portfolio
8.18.5 Xiansheng Pharmaceutical Recent Developments
8.19 Yuanhe Pharmaceutical
8.19.1 Yuanhe Pharmaceutical Comapny Information
8.19.2 Yuanhe Pharmaceutical Business Overview
8.19.3 Yuanhe Pharmaceutical Irbesartan Sales, Value and Gross Margin (2020-2025)
8.19.4 Yuanhe Pharmaceutical Irbesartan Product Portfolio
8.19.5 Yuanhe Pharmaceutical Recent Developments
8.20 Zhejiang Ainuo Pharmaceutical
8.20.1 Zhejiang Ainuo Pharmaceutical Comapny Information
8.20.2 Zhejiang Ainuo Pharmaceutical Business Overview
8.20.3 Zhejiang Ainuo Pharmaceutical Irbesartan Sales, Value and Gross Margin (2020-2025)
8.20.4 Zhejiang Ainuo Pharmaceutical Irbesartan Product Portfolio
8.20.5 Zhejiang Ainuo Pharmaceutical Recent Developments
8.21 Zhejiang Huahai Pharmaceutical
8.21.1 Zhejiang Huahai Pharmaceutical Comapny Information
8.21.2 Zhejiang Huahai Pharmaceutical Business Overview
8.21.3 Zhejiang Huahai Pharmaceutical Irbesartan Sales, Value and Gross Margin (2020-2025)
8.21.4 Zhejiang Huahai Pharmaceutical Irbesartan Product Portfolio
8.21.5 Zhejiang Huahai Pharmaceutical Recent Developments
8.22 Zhuhai Rundu Pharma
8.22.1 Zhuhai Rundu Pharma Comapny Information
8.22.2 Zhuhai Rundu Pharma Business Overview
8.22.3 Zhuhai Rundu Pharma Irbesartan Sales, Value and Gross Margin (2020-2025)
8.22.4 Zhuhai Rundu Pharma Irbesartan Product Portfolio
8.22.5 Zhuhai Rundu Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Irbesartan Value Chain Analysis
9.1.1 Irbesartan Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Irbesartan Sales Mode & Process
9.2 Irbesartan Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Irbesartan Distributors
9.2.3 Irbesartan Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.